Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26953146 | 0.85 | LRRK2 (0.52) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL31735009 | 0.85 | LRRK2 (0.52) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL26953435 | 0.84 | SGK1 (0.44) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL31734984 | 0.84 | SGK1 (0.44) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL31735010 | 0.83 | LRRK2 (0.50) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL26953438 | 0.83 | LRRK2 (0.50) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL31735012 | 0.82 | SGK1 (0.57) | LRRK2SGK1BRAFTNNI3KPRKCI | |
| SCHEMBL26953278 | 0.82 | SGK1 (0.57) | LRRK2SGK1BRAFTNNI3KPRKCI | |
| SCHEMBL31735005 | 0.81 | LRRK2 (0.59) | LRRK2AKT2SGK1BRAFTNNI3K | |
| SCHEMBL26953170 | 0.81 | LRRK2 (0.59) | LRRK2AKT2SGK1BRAFTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | LRRK2 41/4885CCNK 1376/4885CDK12 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.